CSIMarket
 


Zynerba Pharmaceuticals Inc   (ZYNE)
Other Ticker:  
 

Cumulative Zynerba Pharmaceuticals Inc 's Quick Ratio for Trailing Twelve Months Period

ZYNE's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ZYNE Quick Ratio for Trailing Twelve Months Period

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities Growth 17.95 % 7.76 % -7.39 % -13.46 % -4.99 %
Y / Y Cash & cash equivalent Growth -42.44 % -36.3 % -25.32 % -26.05 % -27.15 %
Quick Ratio for Trailing Twelve Months Period 4.74 5.66 6.44 6.77 7.02
Total Ranking # 558 # 531 # 556 # 553 # 627
Seq. Current Liabilities Growth 16.94 % 4.77 % -2.74 % -1.01 % 6.83 %
Seq. Cash & cash equivalent Growth -18.99 % -12.32 % -9.46 % -10.49 % -10.34 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Jun 30 2023
On the trailing twelve months basis Due to increase in Current Liabilities in the II. Quarter to $11 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 4.74 below Zynerba Pharmaceuticals Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 299 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Zynerba Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about ZYNE
Quick Ratio ZYNE in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 300
Sector # 504
S&P 500 # 770


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
9.01 6.77 4.71
(Dec 31 2017)   (Jun 30 2023)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Pyxis Oncology Inc   13.02 
Atai Life Sciences N v   12.85 
Eledon Pharmaceuticals Inc   12.75 
Xenetic Biosciences Inc   12.69 
Immutep Limited  12.59 
Cerevel Therapeutics Holdings Inc   12.58 
Zomedica Corp   12.49 
Annovis Bio inc   12.44 
Dianthus Therapeutics Inc   12.39 
Crinetics Pharmaceuticals Inc   12.20 
Larimar Therapeutics Inc   12.19 
Lumos Pharma Inc   12.08 
Cytokinetics Incorporated  11.99 
Pds Biotechnology Corp  11.89 
Cogent Biosciences Inc   11.87 
Coya Therapeutics Inc   11.83 
Alx Oncology Holdings Inc  11.72 
Kalvista Pharmaceuticals Inc   11.68 
Centessa Pharmaceuticals Plc  11.67 
Inozyme Pharma Inc   11.66 
Reneo Pharmaceuticals Inc   11.41 
Kronos Bio Inc   11.35 
Histogen Inc   11.33 
Lexaria Bioscience Corp   11.28 
Prothena Corporation Public Limited Company  11.13 
Dyne Therapeutics Inc   10.86 
Immix Biopharma Inc   10.82 
Biomea Fusion Inc   10.75 
Forte Biosciences Inc   10.74 
Relmada Therapeutics Inc   10.70 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com